Back grey_arrow_rt.gif
 
 
HCV/HBV/HIV New drug Technology: removal of the lipid coatings from lipid-enveloped viruses
 
 
  Lipid Sciences' Viral Immunotherapy Study Demonstrates Promising Results
 
Vaccine Preparation for SARS Virus Effective in Animal Model
 
PLEASANTON, CA--(Marketwire - June 25, 2007) - Lipid Sciences, Inc. (NASDAQ: LIPD) reported in a submission to the NIH (National Institutes of Health) it has met the study goal of creating a vaccine preparation for SARS (Severe Acute Respiratory Syndrome). This study was funded by the NIH under the auspices of an STTR (Small Business Technology Transfer) grant. Lipid Sciences was successful in using its novel, proprietary delipidation technology to demonstrate proof of principle of the modification of viral particles to be used in preparation of a preventive vaccine against the SARS Coronavirus -- a lipid-enveloped virus of particular concern as a Category C Agent in bio-defense applications. This study validated the hypothesis that a modified SARS viral particle could result in an enhanced immunogenic response in an animal model resulting in both neutralizing antibody and cell-mediated immune responses.
 
Lipid Sciences' Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses by applying the Company's proprietary delipidation technologies. In addition to SARS, conditions that could potentially be impacted by these technologies include HIV, Hepatitis B and Hepatitis C, West Nile, influenza and a broad range of viruses impacting animal health. This study supports the broad application of Lipid Sciences' Viral Immunotherapy technology to a range of respiratory viruses. Most significantly, this study, for the first time, shows the potential of delipidated viruses as immunogens for use as prophylactic vaccines, and validates the broad-based platform opportunity represented by Lipid Sciences' Viral Immunotherapy technology as both a preventive vaccine and a therapeutic treatment.
 
This collaborative research project, performed at Meharry Medical College in Nashville, was led by Dr. Moiz Kitabwalla, Senior Manager, Viral Programs, Lipid Sciences, Inc., and Dr. James E.K. Hildreth, Director of Health Disparities, Meharry Medical College.
 
Dr. Hildreth commented, "The promising results from this study demonstrate the ability of Lipid Sciences' delipidated virus to elicit a unique immune response, which acts as a preventive vaccine, in a respiratory (SARS) virus. Although the study was not statistically powered, the results were so compelling that we intend to publish the data from this study in the near future."
 
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Selective Delipidation and HDL Mimetic Peptides) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, Hepatitis B and Hepatitis C, West Nile, SARS, influenza, and a broad range of viruses impacting animal health.
 
Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; the significant losses we have incurred to date, and our expectation that we will incur substantial losses in the future; the failure of our technologies to prove safe or effective; our inability to obtain regulatory approval for our technologies, which are only in the clinical development stage; delay or failure to complete clinical studies; our inability to add additional clinical trial sites; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; our exposure to product liability claims; and our dependence on key personnel.
 
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.
 
Press releases for Lipid Sciences, Inc. are available on our website: www.lipidsciences.com. If you would like to receive our press releases via email, please contact: info@lipidsciences.com.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org